经口内镜下肌切开术十年美国单中心长期疗效与安全性分析
Kaplan-Meier临床成功率第1年为98%,第5至7年维持91%至92%,无死亡或需手术等严重不良事件;术后每周以上反流症状者占20.5%,pH阳性和食管炎常见但多为轻度。
要点
- POEM长期临床成功率高,≥5年仍超过90%。
- 严重不良事件率3.4%,无死亡或需手术干预。
- 术后反流常见,pH阳性57.1%,食管炎49.8%多为轻度。
核心结论
- POEM长期随访安全且高效,≥5年临床成功率超过90%。
主要发现
- 中位随访30个月,失败29例(定义为术后Eckardt评分>3或需额外治疗);仅13例(2%)失访。
- Kaplan-Meier临床成功率第1、2、3、4、5、6、7年分别为98%、96%、96%、94%、92%、91%、91%。
临床怎么用
- POEM可作为贲门失弛缓症的长效治疗选择,长期疗效维持良好。
- 术后需关注反流症状,并按需行pH监测和内镜评估反流性食管炎。
局限性
- 单中心研究,结果外推需谨慎。
- 中位随访30个月,10年数据仍在积累中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Peroral endoscopic myotomy (POEM) is becoming the treatment of choice for achalasia. Data beyond 3 years are emerging but are limited. We herein report our 10-year experience, focusing on long-term efficacy and safety including the prevalence, management, and sequelae of postoperative reflux. METHODS: This was a single-center prospective cohort study. RESULTS: Six hundred ten consecutive patients received POEM from October 2009 to October 2019, 160 for type 1 achalasia (26.2%), 307 for type II (50.3%), 93 for type III (15.6%), 25 for untyped achalasia (4.1%), and 23 for nonachalasia disorders (3.8%). Two hundred ninety-two patients (47.9%) had prior treatment(s). There was no aborted POEM. Median operation time was 54 minutes. Accidental mucosotomies occurred in 64 patients (10.5%) and clinically significant adverse events in 21 patients (3.4%). No adverse events led to death, surgery, interventional radiology interventions/drains, or altered functional status. At a median follow-up of 30 months, 29 failures occurred, defined as postoperative Eckardt score >3 or need for additional treatment. The Kaplan-Meier clinical success estimates at years 1, 2, 3, 4, 5, 6, and 7 were 98%, 96%, 96%, 94%, 92%, 91%, and 91%, respectively. These are highly accurate estimates because only 13 patients (2%) were missing follow-up assessments. One hundred twenty-five patients (20.5%) had reflux symptoms more than once per week. At a median of 4 months, the pH study was completed in 406 patients (66.6%) and was positive in 232 (57.1%), and endoscopy was completed in 438 patients (71.8%) and showed reflux esophagitis in 218 (49.8%), mostly mild. CONCLUSIONS: POEM is exceptionally safe and highly effective on long-term follow-up, with >90% clinical success at ≥5 years.
引用
- Modayil RJ, Zhang X, Rothberg B, et al. Peroral endoscopic myotomy: 10-year outcomes from a large, single-center U.S. series with high follow-up completion and comprehensive analysis of long-term efficacy, safety, objective GERD, and endoscopic functional luminal assessment. Gastrointest Endosc. 2021. PMID: 33989646. doi:10.1016/j.gie.2021.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。